99 related articles for article (PubMed ID: 29301826)
21. circPTPN22 attenuates immune microenvironment of pancreatic cancer via STAT3 acetylation.
He Y; Han P; Chen C; Xie S; Zhang H; Song Y; Hu H; Zhao Q; Lian C
Cancer Gene Ther; 2023 Apr; 30(4):559-566. PubMed ID: 34471233
[TBL] [Abstract][Full Text] [Related]
22. Mutated p53 in HGSC-From a Common Mutation to a Target for Therapy.
Saleh A; Perets R
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298679
[TBL] [Abstract][Full Text] [Related]
23. Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.
Tay BQ; Wright Q; Ladwa R; Perry C; Leggatt G; Simpson F; Wells JW; Panizza BJ; Frazer IH; Cruz JLG
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065557
[TBL] [Abstract][Full Text] [Related]
24. Monitoring T Cells Responses Mounted by Therapeutic Cancer Vaccines.
Lim KP; Zainal NS
Front Mol Biosci; 2021; 8():623475. PubMed ID: 33937323
[TBL] [Abstract][Full Text] [Related]
25. Role of myeloid-derived suppressor cells in metastasis.
Cole K; Pravoverov K; Talmadge JE
Cancer Metastasis Rev; 2021 Jun; 40(2):391-411. PubMed ID: 33411082
[TBL] [Abstract][Full Text] [Related]
26. Development of Therapeutic Vaccines for Ovarian Cancer.
Chow S; Berek JS; Dorigo O
Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33167428
[TBL] [Abstract][Full Text] [Related]
27. Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer.
Martinez A; Delord JP; Ayyoub M; Devaud C
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630708
[TBL] [Abstract][Full Text] [Related]
28. Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells.
Moody R; Wilson K; Jaworowski A; Plebanski M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183059
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update.
Dörrie J; Schaft N; Schuler G; Schuler-Thurner B
Pharmaceutics; 2020 Jan; 12(2):. PubMed ID: 31979205
[TBL] [Abstract][Full Text] [Related]
30. Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Sakellariou-Thompson D; Forget MA; Hinchcliff E; Celestino J; Hwu P; Jazaeri AA; Haymaker C; Bernatchez C
Cancer Immunol Immunother; 2019 Nov; 68(11):1747-1757. PubMed ID: 31602489
[TBL] [Abstract][Full Text] [Related]
31. TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.
Kaur HB; Lu J; Guedes LB; Maldonado L; Reitz L; Barber JR; De Marzo AM; Tomlins SA; Sfanos KS; Eisenberger M; Schaeffer EM; Joshu CE; Lotan TL
Hum Pathol; 2019 May; 87():95-102. PubMed ID: 30851334
[TBL] [Abstract][Full Text] [Related]
32. Review of Immune Therapies Targeting Ovarian Cancer.
Fan CA; Reader J; Roque DM
Curr Treat Options Oncol; 2018 Nov; 19(12):74. PubMed ID: 30430276
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers.
Chung V; Kos FJ; Hardwick N; Yuan Y; Chao J; Li D; Waisman J; Li M; Zurcher K; Frankel P; Diamond DJ
Clin Transl Oncol; 2019 Mar; 21(3):363-372. PubMed ID: 30094792
[TBL] [Abstract][Full Text] [Related]
34. The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy.
Rodriguez GM; Galpin KJC; McCloskey CW; Vanderhyden BC
Cancers (Basel); 2018 Jul; 10(8):. PubMed ID: 30042343
[TBL] [Abstract][Full Text] [Related]
35. p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Hardwick NR; Frankel P; Ruel C; Kilpatrick J; Tsai W; Kos F; Kaltcheva T; Leong L; Morgan R; Chung V; Tinsley R; Eng M; Wilczynski S; Ellenhorn JDI; Diamond DJ; Cristea M
Clin Cancer Res; 2018 Mar; 24(6):1315-1325. PubMed ID: 29301826
[TBL] [Abstract][Full Text] [Related]
36. p53MVA therapy in patients with refractory gastrointestinal malignancies elevates p53-specific CD8+ T-cell responses.
Hardwick NR; Carroll M; Kaltcheva T; Qian D; Lim D; Leong L; Chu P; Kim J; Chao J; Fakih M; Yen Y; Espenschied J; Ellenhorn JD; Diamond DJ; Chung V
Clin Cancer Res; 2014 Sep; 20(17):4459-70. PubMed ID: 24987057
[TBL] [Abstract][Full Text] [Related]
37. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Dijkgraaf EM; Santegoets SJ; Reyners AK; Goedemans R; Nijman HW; van Poelgeest MI; van Erkel AR; Smit VT; Daemen TA; van der Hoeven JJ; Melief CJ; Welters MJ; Kroep JR; van der Burg SH
Oncotarget; 2015 Oct; 6(31):32228-43. PubMed ID: 26334096
[TBL] [Abstract][Full Text] [Related]
38. Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian Cancer.
Kos FJ; Frankel P; Cristea M; Eng M; Tinsley R; Dempsey S; Ruel N; Stewart D; Dellinger TH; Diamond DJ
Cancer Res Commun; 2023 Dec; 3(12):2585-2595. PubMed ID: 38032111
[TBL] [Abstract][Full Text] [Related]
39. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
40. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
Cochrane Database Syst Rev; 2011 Oct; (10):CD007927. PubMed ID: 21975775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
